In this article, we provide an overview of the tumor immune environment in cancer tissues and programmed death 1 (PD1)/programmed death ligand 1 (PD-L1) expression in cervical cancer tissues, and we describe results from the KEYNOTE-158 trial and the latest CheckMate 358 trial. This evidence concerns the gene CD274 and cervical carcinoma.